title: Immunosuppressive properties of mesenchymal stem cells derived from bone marrow of patient with hematological malignant diseases.
abstract: Mesenchymal stem cells (MSCs) have received much attention because of their capabilities of differentiating into multiple mesenchymal lineages and supporting hematopoiesis. Recently, MSCs have gained further interests after the demonstration of an immunosuppressive role. However, it's still unclear whether the immunosuppressive capability of MSCs will be altered with disease state. In this study, our results showed that MSCs derived from patients with lymphoblastic leukemia (ALL), Hodgkin disease (HD), and non-Hodgkin lymphoma (NHL) capable of suppressing the proliferation of T-lymphocyte stimulated in a mixed-lymphocyte reaction (MLR). The immunosuppressive effect of MSCs derived from ALL, HD and NHL on T-cell proliferation was dose-dependent. The supernatants of MSCs derived from ALL, HD and NHL had effect on T-cell proliferation. By using neutralising monoclonal antibodies, we found that transforming growth factor beta1 (TGFbeta1) and hepatocyte growth factor were major mediators of T-cell suppression by MSCs derived from ALL, HD and NHL. Although MSCs derived from patients with myelodysplastics syndromes (MDS) could inhibit T-cell proliferation stimulated with mitogen or in MLR, the inhibitory effect of MDS-MSCs was impaired. However, adherent cells derived from patients with acute myeloid leukemia (AML) showed abnormal immunomodulatory functions. Adherent cells derived from AML failed to suppress the proliferation of T-cell stimulated in MLR.
authors.affiliation: Department of Hematology and Oncology, the Oncology Hospital of Tianjin Medical University, Tianjin, PR China.
authors.forename: Zhao
authors.initials: Z
authors.lastname: Zhi-Gang
authors.forename: Li
authors.initials: L
authors.lastname: Wei-Ming
authors.forename: Chen
authors.initials: C
authors.lastname: Zhi-Chao
authors.forename: You
authors.initials: Y
authors.lastname: Yong
authors.forename: Zou
authors.initials: Z
authors.lastname: Ping
mesh_terms: D001854:Bone Marrow Cells / Q000276:immunology*; D019337:Hematologic Neoplasms / Q000276:immunology*; D017228:Hepatocyte Growth Factor / Q000276:immunology*; D006689:Hodgkin Disease; D006801:Humans; D007155:Immunologic Factors; D007165:Immunosuppression Therapy; D007959:Lymphocyte Culture Test, Mixed; D008228:Lymphoma, Non-Hodgkin; D059630:Mesenchymal Stem Cells / Q000276:immunology*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma; D013601:T-Lymphocytes / Q000276:immunology; D016212:Transforming Growth Factor beta / Q000276:immunology*
chemical_list: D007155:Immunologic Factors; D016212:Transforming Growth Factor beta; D017228:Hepatocyte Growth Factor